NASDAQ:MGRX Mangoceuticals (MGRX) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free MGRX Stock Alerts $0.26 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.25▼$0.2750-Day Range$0.15▼$0.3052-Week Range$0.14▼$2.38Volume60,160 shsAverage Volume849,182 shsMarket Capitalization$6.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Mangoceuticals alerts: Email Address Ad Awesomely, LLCAutomatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. Just click here now to watch my presentation for free. About Mangoceuticals Stock (NASDAQ:MGRX)Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.Read More MGRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MGRX Stock News HeadlinesMay 2, 2024 | finance.yahoo.comMangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity RequirementMay 2, 2024 | globenewswire.comMangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq's Minimum Stockholders' Equity RequirementMay 3, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 25, 2024 | finance.yahoo.comMangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive CareApril 13, 2024 | investing.comMangoceuticals partners with Emifarma for ED product developmentApril 12, 2024 | globenewswire.comMangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) ProductsApril 10, 2024 | finance.yahoo.comThis Mangoceuticals Insider Increased Their Holding In The Last YearMarch 12, 2024 | finance.yahoo.comMangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) TreatmentMay 3, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.March 12, 2024 | globenewswire.comMangoRx Officially Launches ‘PRIME' by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) TreatmentFebruary 27, 2024 | benzinga.comMangoceuticals Stock (NASDAQ:MGRX), Quotes and News SummaryFebruary 20, 2024 | finance.yahoo.comMangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue GrowthFebruary 20, 2024 | globenewswire.comMangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue GrowthFebruary 13, 2024 | finance.yahoo.comMangoceuticals, Inc. (MGRX)February 13, 2024 | finance.yahoo.comMANGORX AWARDS SAN FRANCISCO TEAM FREE MANGORX ED PRODUCTS FOR ONE YEAR FOLLOWING BIG GAME LOSS TO KANSAS CITYFebruary 8, 2024 | msn.comWhy Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionFebruary 8, 2024 | msn.comWhy Disney Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving PremarketFebruary 6, 2024 | stockhouse.comMANGORX TO OFFER THE BIG GAME'S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE… SPIRITSFebruary 6, 2024 | finance.yahoo.comMANGORX TO OFFER THE BIG GAME’S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE… SPIRITSFebruary 5, 2024 | stockhouse.comMangoRx Accepting Pre Orders for its "PRIME", by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) ProductFebruary 5, 2024 | finance.yahoo.comMangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) ProductJanuary 19, 2024 | finance.yahoo.comMangoRx’s Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11December 15, 2023 | finance.yahoo.comMangoceuticals, Inc. Announces Pricing of $1,200,000 Public OfferingDecember 15, 2023 | investorplace.comWhy Is Mangoceuticals (MGRX) Stock Down 33% Today?December 13, 2023 | finance.yahoo.comMANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCTDecember 12, 2023 | msn.comMangoceuticals files to sell 5M shares of common stockDecember 6, 2023 | finance.yahoo.comMangoceuticals Launches MangoRx Mexico Subsidiary, Paving the Way for Over-the-Counter Retail of Erectile Dysfunction Line of Products in Latin AmericaSee More Headlines Receive MGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mangoceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today5/03/2024Next Earnings (Estimated)7/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:MGRX CUSIPN/A CIK1938046 Webwww.mangorx.com Phone833-626-4679FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,210,000.00 Net Margins-1,260.81% Pretax Margin-1,260.19% Return on Equity-411.62% Return on Assets-366.32% Debt Debt-to-Equity RatioN/A Current Ratio3.88 Quick Ratio3.79 Sales & Book Value Annual Sales$730,000.00 Price / Sales8.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book6.60Miscellaneous Outstanding Shares24,620,000Free Float13,196,000Market Cap$6.50 million OptionableNot Optionable Beta1.27 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Eugene M. Johnston (Age 60)Chief Financial Officer Comp: $14kMs. Amanda Elizabeth Hammer (Age 38)Chief Operating Officer Comp: $105.42kKey CompetitorsGreenbrook TMSNASDAQ:GBNHFBioRestorative TherapiesNASDAQ:BRTXOntrakNASDAQ:OTRKProcessa PharmaceuticalsNASDAQ:PCSAHoth TherapeuticsNASDAQ:HOTHView All Competitors MGRX Stock Analysis - Frequently Asked Questions How have MGRX shares performed in 2024? Mangoceuticals' stock was trading at $0.2769 at the beginning of the year. Since then, MGRX stock has decreased by 4.7% and is now trading at $0.2640. View the best growth stocks for 2024 here. Are investors shorting Mangoceuticals? Mangoceuticals saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 197,600 shares, a drop of 71.4% from the March 31st total of 692,100 shares. Based on an average daily trading volume, of 904,900 shares, the short-interest ratio is presently 0.2 days. Approximately 1.5% of the company's stock are sold short. View Mangoceuticals' Short Interest. When is Mangoceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 1st 2024. View our MGRX earnings forecast. How were Mangoceuticals' earnings last quarter? Mangoceuticals, Inc. (NASDAQ:MGRX) posted its quarterly earnings results on Monday, April, 1st. The company reported ($0.13) earnings per share for the quarter. The company earned $0.24 million during the quarter. Mangoceuticals had a negative net margin of 1,260.81% and a negative trailing twelve-month return on equity of 411.62%. When did Mangoceuticals IPO? Mangoceuticals (MGRX) raised $5 million in an initial public offering (IPO) on Tuesday, March 21st 2023. The company issued 1,300,000 shares at $4.00 per share. Boustead Securities acted as the underwriter for the IPO. How do I buy shares of Mangoceuticals? Shares of MGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MGRX) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGold ManiaStansberry ResearchThe Gold Grab of the CenturyColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mangoceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
